You are here : Home > The Institute > News > The identification of biomarkers by metabolomics should allow a better follow-up of cirrhotic patients

Scientific result | Metabolomics | Biomarkers | Diseases

The identification of biomarkers by metabolomics should allow a better follow-up of cirrhotic patients


​Researchers from SPI, in collaboration with teams from an European foundation, EF Clif, carried out global and targeted metabolomic analyzes which made possible to highlight, in cirrhotic patients, an activation of the kynurenine metabolic pathway (tryptophan degradation pathway). The imbalance of this pathway is probably the cause of the symptoms observed during cirrhotic decompensation, when the body can no longer compensate for liver dysfunctions.

Published on 7 February 2019

​Abstract of the original paper

Systemic inflammation (SI) is involved in the pathogenesis of acute decompensation (AD) and acute‐on‐chronic liver failure (ACLF) in cirrhosis. In other diseases, SI activates tryptophan (Trp) degradation through the kynurenine pathway (KP), giving rise to metabolites that contribute to multiorgan/system damage and immunosuppression.
In the current study, we aimed to characterize the KP in patients with cirrhosis, in whom this pathway is poorly known. The serum levels of Trp, key KP metabolites (kynurenine and kynurenic and quinolinic acids), and cytokines (SI markers) were measured at enrollment in 40 healthy subjects, 39 patients with compensated cirrhosis, 342 with AD (no ACLF) and 180 with ACLF, and repeated in 258 patients during the 28‐day follow‐up. Urine KP metabolites were measured in 50 patients with ACLF. Serum KP activity was normal in compensated cirrhosis, increased in AD and further increased in ACLF, in parallel with SI; it was remarkably higher in ACLF with kidney failure than in ACLF without kidney failure in the absence of differences in urine KP activity and fractional excretion of KP metabolites. The short‐term course of AD and ACLF (worsening, improvement, stable) correlated closely with follow‐up changes in serum KP activity. Among patients with AD at enrollment, those with the highest baseline KP activity developed ACLF during follow‐up. Among patients who had ACLF at enrollment, those with immune suppression and the highest KP activity, both at baseline, developed nosocomial infections during follow‐up. Finally, higher baseline KP activity independently predicted mortality in patients with AD and ACLF. 

Conclusion:
 Features of KP activation appear in patients with AD, culminate in patients with ACLF, and may be involved in the pathogenesis of ACLF, clinical course, and mortality.

Top page